AIDS Research and Human Retroviruses

Journal

Publication Venue For

  • The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission.  35:219-228. 2019
  • Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.  35:123-128. 2019
  • Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.  34:916-921. 2018
  • Short Communication: Apoptotic Membrane Microparticles Quantified by Fluorescent Bead-Based Assay Are Elevated in HIV and SIV Infections.  34:446-448. 2018
  • HIV Self-Testing in Lusaka Province, Zambia: Acceptability, Comprehension of Testing Instructions, and Individual Preferences for Self-Test Kit Distribution in a Population-Based Sample of Adolescents and Adults.  34:254-260. 2018
  • Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.  33:778-783. 2017
  • HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights.  33:749-759. 2017
  • Amino Acid Concentrations in HIV-Infected Youth Compared to Healthy Controls and Associations with CD4 Counts and Inflammation.  33:681-689. 2017
  • Associations between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy among Patients Living with HIV.  33:534-545. 2017
  • Duration of Influenza Virus Shedding among HIV-Infected Adults in the cART Era, 2010-2011.  32:1180-1186. 2016
  • Increased Steady-State Memory B Cell Subsets among High-Risk Participants in an HIV Vaccine Trial.  32:1143-1148. 2016
  • Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/Hepatitis C virus-coinfected patients.  32:325-328. 2016
  • Complement component 3 is associated with metabolic comorbidities in older HIV-positive adults.  32:271-278. 2016
  • High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy.  32:59-67. 2016
  • Loss of Virologic Control and Severe Pneumocystis pneumonia in an HIV-Infected Patient Receiving Chemotherapy for Non-Small Cell Lung Cancer.  32:4-5. 2016
  • Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function.  31:1278-1296. 2015
  • Obesity is Associated with Race/Sex Disparities in Diabetes and Hypertension Prevalence, but Not Cardiovascular Disease, among HIV-Infected Adults.  31:898-904. 2015
  • A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds.  31:1055-1059. 2015
  • Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.  31:961-966. 2015
  • Quantitative evaluation of an instrument to identify chronic pain in HIV-infected individuals.  31:623-627. 2015
  • Short communication: Viral suppression is associated with increased likelihood of colorectal cancer screening among persons living with HIV/AIDS.  31:519-524. 2015
  • The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV+ African Americans.  30:233-240. 2014
  • A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010).  30:184-189. 2014
  • Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia.  30:949-955. 2014
  • LL-37 concentrations and the relationship to vitamin D, immune status, and inflammation in HIV-infected children and young adults.  30:670-676. 2014
  • Short communication: Late refills during the first year of antiretroviral therapy predict mortality and program failure among HIV-infected adults in Urban Zambia.  30:74-77. 2014
  • Short communication: Plasmacytoid dendritic cells from HIV-1 elite controllers maintain a gut-homing phenotype associated with immune activation.  30:1213-1215. 2014
  • Relationships among HIV infection, metabolic risk factors, and left ventricular structure and function.  29:1151-1160. 2013
  • Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the southeastern United States.  29:1068-1074. 2013
  • Short communication: Lack of occult HIV infection among non-AIDS-defining cancer patients in three academic oncology clinics in the United States.  29:887-891. 2013
  • Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes.  29:698-703. 2013
  • Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: Role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation.  29:493-500. 2013
  • Immunologic risk factors for early mortality after starting antiretroviral therapy in HIV-Infected Zambian children.  29:479-487. 2013
  • Maraviroc observational study: The impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.  29:105-111. 2013
  • Short communication: New HIV infections at southern new england academic institutions: Implications for prevention.  29:25-29. 2013
  • Short communication: HIV type 1 escapes inactivation by saliva via rapid escape into oral epithelial cells.  28:1574-1578. 2012
  • Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV Type 1-infected subjects over 48 weeks.  28:1184-1195. 2012
  • Phylodynamic and phylogeographic patterns of the HIV type 1 subtype F1 parenteral epidemic in Romania.  28:961-966. 2012
  • Short communication routine HIV testing in the emergency department: Assessment of patient perceptions.  28:352-356. 2012
  • Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy.  28:259-264. 2012
  • Cystatin C and baseline renal function among HIV-infected persons in the SUN study.  28:148-155. 2012
  • The role of toxicity-related regimen changes in the development of antiretroviral resistance.  27:957-963. 2011
  • Identification of three immunologic correlates for HIV type 1 pathogenesis in Youth.  27:639-646. 2011
  • Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.  27:469-486. 2011
  • Darunavir outcomes study: Comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks.  26:1279-1285. 2010
  • Erratum: Treatment with Recombinant Growth Hormone Is Associated with Modest Improvement in CD4 Lymphocyte Reconstitution in HIV-Infected Persons on Antiretroviral Therapy: Results of ACTG A5174 (AIDS Research and Human Retroviruses (2010) 26 (425-432)).  26:839. 2010
  • Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: Results of ACTG A5174.  26:425-432. 2010
  • Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.  26:279-291. 2010
  • Short-cycle therapy in adolescents after continuous therapy with established viral suppression: The impact on viral load suppression.  25:555-561. 2009
  • Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults..  25:103-114. 2009
  • Short-term discontinuation of HAART regimens more common in vulnerable patient populations.  24:1347-1355. 2008
  • Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG.  24:1167-1174. 2008
  • Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy.  24:1031-1035. 2008
  • An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: The Biojector 2000 open-label safety study (BOSS).  24:805-813. 2008
  • Solution structure of a calmodulin-binding domain in the carboxy-terminal region of HIV type 1 gp160.  24:607-616. 2008
  • Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria.  23:1587-1591. 2007
  • The complexity of circulating HIV type 1 strains in Oyo State, Nigeria.  23:1020-1025. 2007
  • Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.  23:67-76. 2007
  • Subtype-specific patterns in HIV type 1 reverse transcriptase and protease in Oyo State, Nigeria: Implications for drug resistance and host response.  22:770-779. 2006
  • Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: Week 60 results from the PACTG 381 cohort.  22:213-221. 2006
  • Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.  22:232-239. 2006
  • Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy.  22:125-131. 2006
  • Sustained HIV viral suppression following treatment interruption: An observational study.  22:40-44. 2006
  • Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: Case reports and review of the literature.  21:753-756. 2005
  • Predictors of HIV serostatus among HIV discordant couples in Lusaka, Zambia and female antenatal clinic attendants in Kigali, Rwanda.  21:5-12. 2005
  • Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.  20:1037-1045. 2004
  • Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals.  20:972-988. 2004
  • AZT enhances osteoclastogenesis and bone loss.  20:608-620. 2004
  • Incidence and risk factors for sexually transmitted infections among women in an Alabama HIV clinic.  20:577-583. 2004
  • Erratum: CD8+ CD38+ T cells but not HIV type 1 RNA viral load predict CD4+ cell loss in a predominantly minority female HIV+ adolescent population (AIDS Research and Human Retroviruses (2004) 22 (263-269)).  20:575. 2004
  • CD8+CD88+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV + adolescent population.  20:263-269. 2004
  • Development of a novel human immunodeficiency virus type 1 subtyping tool, subtype analyzer (STAR): Analysis of subtype distribution in London.  20:457-464. 2004
  • HLA Allele Sharing and HIV Type 1 Viremia in Seroconverting Zambians with Known Transmitting Partners.  20:19-25. 2004
  • HIV Protease Inhibitor Ritonavir Induces Lipoatrophy in Male Mice.  19:1141-1150. 2003
  • T Cell Responses in HIV Type 1-Infected Adolescent Minorities Share Similar Epitope Specificities with Whites Despite Significant Differences in HLA Class I Alleles.  19:1017-1026. 2003
  • Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: In vitro expression and immune responses in DNA-vaccinated mice.  19:817-823. 2003
  • CD4+and CD8+T cell receptor repertoire perturbations with normal levels of T cell receptor excision circles in HIV-infected, therapy-naive adolescents.  19:487-495. 2003
  • The relationships between substance abuse, psychosocial variables, and natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents.  19:399-408. 2003
  • Detection of mucosal antibodies in HIV type 1-infected individuals.  18:1291-1300. 2002
  • HIV type 1 abrogates TAP-mediated transport of antigenic peptides presented by MHC class I.  18:1319-1325. 2002
  • Increased proliferation within T lymphocyte subsets of HIV-infected adolescents.  18:1301-1310. 2002
  • Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice.  18:909-916. 2002
  • CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: Limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy.  18:403-412. 2002
  • Position paper on therapeutic drug monitoring of antiretroviral agents.  18:825-834. 2002
  • The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.  18:685-693. 2002
  • Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.  17:1379-1385. 2001
  • Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents.  17:543-552. 2001
  • Analysis of human immunodeficiency virus type 1 containing HERV-K protease.  16:1973-1980. 2000
  • HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays.  16:1149-1156. 2000
  • Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis.  16:1123-1133. 2000
  • Relationship of CD4+ T cell counts and HIV type 1 viral loads in untreated, infected adolescents.  16:959-963. 2000
  • False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens.  16:595-602. 2000
  • Induction of immune responses to SIV antigens by mucosally administered vaccines.  15:1469-1476. 1999
  • Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.  15:1413-1417. 1999
  • Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals.  15:1063-1071. 1999
  • MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates.  15:921-930. 1999
  • HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection.  15:317-324. 1999
  • HIV- 1(MN) recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1(MN) recombinant glycoprotein 120 vaccine.  15:115-132. 1999
  • The changing face of AIDS research and human retroviruses: A new forum to display your ART-work.  14:721. 1998
  • Mucosal immunity in the female reproductive tract: Correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation.  14. 1998
  • Effects of tapering doses of oral prednisone on viral load among HIV- infected patients with unexplained weight loss.  13:1533-1537. 1997
  • A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers.  13:301-304. 1997
  • Characterization of the expression and immunogenicity of poliovirus replicons that encode Simian immunodeficiency virus SIV(mac)239 gag or envelope SU proteins.  13:53-62. 1997
  • Analysis of West African hunters for foamy virus infections.  12:1725-1730. 1996
  • HIV-specific cellular and humoral immune responses in primary HIV infection.  12:1129-1140. 1996
  • Clinical Evaluation of Branched DNA Signal Amplification for Quantifying HIV Type 1 in Human Plasma.  11:353-361. 1995
  • Polyclonal Rabbit Antisera that Detect the Vpr Protein of SIVSM and SIVMAC on Immunoblots of Purified Virions.  11:405-408. 1995
  • Mucosal immunity in the female genital tract: Relevance to vaccination efforts against the human immunodeficiency virus.  10. 1994
  • CHARACTERIZATION OF VIRGIN AND MEMORY TYPE IFN-GAMMA PRODUCING CD8(+) T-LYMPHOCYTES IN SIV-INFECTED RHESUS MACAQUES.  10:S67-S67. 1994
  • Conference on advances in AIDS vaccine development - 1993 summary: Cytotoxic T-cell immunity workshop.  10. 1994
  • Conference on advances in AIDS vaccine development - 1993 summary: Mucosal immunity workshop.  10. 1994
  • Evolving Understanding of the Immunopathogenesis of HIV.  10:887-892. 1994
  • HIV-1 Sequence Subtype D in the United States.  10:625-627. 1994
  • New approaches for mucosal vaccines for AIDS: Encapsidation and serial passage of poliovirus replicons that express HIV-1 proteins on infection.  10. 1994
  • MUCOSAL VACCINE FOR AIDS - ORAL IMMUNIZATION WITH HIV GP120 IN COMBINATION WITH LIPOSOME AND CHOLERA-TOXIN INDUCES ANTIGEN-SPECIFIC IGA PRODUCING CELLS.  9:S36-S36. 1993
  • Isotype of anti-SIV responses in infected rhesus macaques and in animals immunized by mucosal routes.  8:1389. 1992
  • International Standard Serial Number (issn)

  • 0889-2229
  • Electronic International Standard Serial Number (eissn)

  • 1931-8405